A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.

1. Incidence of dose limiting toxicities., 2. Frequency and severity of Adverse Events and Serious Adverse Events., 3. Changes between baseline and post baseline safety assessments., 4. Frequency of dose interruptions and dose reductions., 5. Frequency of Adverse Events leading to discontinuation of study treatment(s)., 6. Overall response rate measured by RECIST v1.1 criteria per Independent Review Committee.